March 07, 2024

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

March 06, 2024

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

February 05, 2024

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

January 19, 2024

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

January 16, 2024

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

January 16, 2024

Vaxart, Inc. Announces Management Change

December 21, 2023

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

November 02, 2023

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

November 02, 2023

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

October 26, 2023

Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2

October 11, 2023

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

September 21, 2023

Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference

September 06, 2023

Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

August 03, 2023

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

July 27, 2023

Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3

July 06, 2023

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

June 26, 2023

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

June 21, 2023

Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET

June 07, 2023

Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock

June 06, 2023

Vaxart, Inc. Announces Proposed Public Offering of Common Stock

June 06, 2023

Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate

May 31, 2023

Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET

May 04, 2023

Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results  

April 28, 2023

Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4

March 29, 2023

Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6

March 17, 2023

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

March 15, 2023

Vaxart Provides Business Update and Full Year 2022 Financial Results

March 08, 2023

Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

February 14, 2023

Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate

December 19, 2022

Vaxart Names Phillip Lee as Chief Financial Officer

December 01, 2022

Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers

November 22, 2022

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

November 08, 2022

Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results

October 20, 2022

Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

October 10, 2022

Vaxart to Present at World Vaccine Congress Europe 2022 on October 13

September 07, 2022

Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 01, 2022

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

August 31, 2022

Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

August 31, 2022

Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer

August 25, 2022

Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors

August 08, 2022

Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results

August 08, 2022

Vaxart Appoints W. Mark Watson to its Board of Directors

August 05, 2022

Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4

July 28, 2022

Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8

July 27, 2022

Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET

July 20, 2022

Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

July 14, 2022

Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022

July 01, 2022

Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET

June 30, 2022

Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model

June 16, 2022

Vaxart to Host Investor Q&A Webcast